Summary In the LMCEI study using a single course of megatherapy most of the relapses occurred during the first 2 years after autologous bone marrow transplantation. A second pilot study (LMCE2) was therefore set up using a double harvest/double graft approach with two different megatherapy regimens. Objectives were to test the role of increased dose intensity on response status, relapse pattern and overall survival.
Thirty-three patients (20 boys, 13 girls) with a median age of 53 months at first megatherapy (range, 17-202 months) entered this study. They were cases either with refractory disease in partial response after second line treatment for stage 4 neuroblastoma (n = 25) or after relapse from stage 4 (n = 5) or stage 3 disease (n = 3).
All patients received Etoposid and/or Cisplatinum (or Carboplatin) containing treatments before megatherapy. The first megatherapy regimen was a combination of Tenoposid, Carmustine and Cisplatinum (or Carboplatin) , the second applied Vincristin, Melphalan and Total Body Irradiation. The first harvest was scheduled 4 weeks after the last chemotherapy, the second 60 to 90 days after megatherapy. All marrows were purged in vitro by an immunomagnetic technique. Median follow up time since first megatherapy is 56 months.
Response rates for evaluable patients were 65% (complete response rate: 16%) for megatherapy I and 60% (complete response rate:25%) for megatherapy 2. Considering that only patients with delayed response or relapse were eligible for this pilot study the overall survival was encouraging with 36% at 2 years and still 32% at 5 years. The costs for these survival rates were high in terms of morbidity (four early and four late toxic deaths; toxic death rate:24%). Double harvesting may have the disadvantage of delayed engraftments related in part to a disturbance of marrow microenvironment by megatherapy 1. This double megatherapy approach achieved a prolonged relapse free interval (median 11 months, range 2-31 months) in patients reaching megatherapy 2 and justifies further evaluation of concepts with consecutive dose-escalation.
Stage 4 Neuroblastoma in children over one year of age at diagnosis is the most common childhood malignancy before the age of five (Carlsen et al., 1986) . Historical groups only had a survival expectancy of about 10% at 3 years with conventional chemotherapy (Shafford et al., 1984; Hartmann et al., 1983; Letourneau et al., 1985; Rosen et al., 1984) . More intensive induction treatments (Shafford et al., 1984; Bernard et al., 1987 , Philip et al., 1987b Hartmann et al., 1988; Berthold et al., 1990; Pinkerton et al., 1990; Kushner et al., 1987; Philip et al., 1988) are now able to achieve initial response rates up to 90%. Megatherapy (MGT) and other consolidation modalities further contributed to improve survival rates (Pritchard et al., 1982; Graham-Pole et al., 1984; August et al., 1984; D'Angio et al., 1985; Pritchard et al., 1986; Pinkerton et al., 1987; Graham-Pole 1991a; Dini et al., 1991; Zucker et al., 1991; Philip et al., 1985 , Philip et al., 1987a Philip et al., 1991; Hartmann et al., 1986; Hartmann et al., 1987 , Seeger et al., 1991 . Although survival at 2 years has clearly improved to approximately 40%, the long-term survival remains unlikely for at least 75% of the patients due to later disease progressions or relapse. .
Our group has previously reported an intensified induction treatment (Bernard et al., 1987) and consolidation with Vincristin (VCR), Melphalan (L-PAM) and Total Body Irradiation (TBI) followed by purged Autologous Bone Marrow Transplantation (ABMT) in 72 consecutive unselected patients with stage 4 neuroblastoma over one year of age at diagnosis (Philip et al., 1987a; Philip et al., 1991) . A significant impact on progression-free survival at 2 years was achieved, but it is not possible to differentiate if this overall improvement is related to intensified induction or MGT followed by BMT or both. No relapses were observed before 4 months post-MGT in the LMCE1 study with the majority occurring during the following two years.
These results served as the background to a pilot study in a group of patients who were not eligible for the LMCE1 study (Bernard et al., 1987; Philip et al., 1987a; Philip et al., 1991) . These patients showed delayed response to second or third line induction treatments or entered the study after relapse. In an attempt to further improve response and to decrease the incidence of early relapse, patients received two different courses of MGT within a 3 months interval. Bone marrow was harvested twice, before and after the first MGT (MGT1). The objectives of this study were to assess the effect of increased dose intensity on response as well as on relapse pattern and overall survival. (Combaret et al., 1989b; Favrot et al., 1987 Favrot et al., , 1989 with no detectable residual tumour cells after the procedure (detection limit 10' tumour cells). Patients receiving allogenic BMT are not included in this analysis.
Treatments
First line chemotherapy is the original treatment protocol which the patients entered at diagnosis. Second line chemotherapy refers to the change in treatment policy due to minor response to first line treatment. Surgical attempts to remove the primary tumour were undertaken in all but one patient. Results of surgery as part of pre-MGT treatments are given in detail on Table I . In fact, complete excision of primary tumours was achieved (PT1/PT3A) in only 8 patients of the PR group. For relapse patients results of surgery are detailed for first line treatments and was performed only in five during second line treatment. Three patients had received additional local radiotherapy before entering the LMCE2 study. A summary is given in Table I .
Pretreatments duration of < 12 months was observed in 17 patients and included one stage 4 relapse patient not previously grafted. Sixteen patients had longer intervals between diagnosis and date of entry in the double graft programm. Nine of them were patients that never had achieved complete remission and their pretreatments varied from 12 to 20 months. Seven patients in relapse had intervals from 15 to 52 months (exact relapse free interval not reported).
Following inclusion, two courses of Etoposid (VP16) and Cisplatinum (CDDP) (n = 10) or VP16 and Carboplatin (CBDCA) (n = 8) were given to increase response. Fifteen patients had pretreatment with other CDDP containing combinations. As shown in Table II , a first harvest was scheduled 4 weeks after the last chemotherapy. The first MGT regimen (MGTI), was a combination of Tenoposid (VM26), Bichloronitrosourea (BCNU) and CDDP or CBDCA and was given within 2 weeks after harvest. A second harvest was performed 60 to 90 days post-MGTI. The second MGT regimen (MGT2) was a combination of VCR, L-PAM and TBI (Philip et al., 1987a) (Table II) . Seven of the 33 patients had received granulomacrophage colony stimulating factor (GMCSF) either at MGT1 (one patient or MGT2 (6 patients) as part of a randomised study of this agent (Philip et al., 1992) .
Statistical methods Probability of survival was analysed according to the Kaplan-Meier Method (Kaplan & Meier, 1958) regarding the date of first ABMT as day 0 for survival estimation. All events of death (toxicity or disease related) were included for survival estimations. The median follow up time is 70 months since diagnosis and is 56 months after MGT1.
Patients
Thirty-three patients were included in this LMCE2 pilot study from 04/85 to 08/88. Twenty were males and 13 females with a median age of 53 months (range: 17-202 months) before first graft.
A total of 25 patients with stage 4 neuroblastoma at diagnosis were in PR after at least second line induction treatments. Thirteen patients showed only minor response to first line protocols and were consequently improved to PR status with courses of VP16 and high dose CDDP or CBDCA as previously reported (Philip et al., 1987b; Hartmann et al., 1988; Philip et al., 1988) . None of these patients were eligible for the LMCE1 study in which a single MGT regimen is given. Twelve patients received pretreatments outside France: Germany (four cases), Israel (two cases), Italy (two cases), Switzerland (two cases), USA (one case), England (one case) and joined the LMCE2 protocol also in delayed PR after more than first line treatments.
Nineteen of 25 had bone marrow involvement at the time of the first harvest and the first MGT. Fourteen had bone involvement, 7/23 had elevated catecholamine secretion (two patients not tested) and 14 had primary, locoregional residual tumour (patient no 9 showed a local progression just before MGT).
Eight patients were included in the LMCE2 protocol after relapse from stage 4 (five patients) or stage 3 disease (three patients). Seven patients were still sensitive to the VP16-CDDP rescue regimen as previously described (Philip et al., 1987b) and were defined as SR and received MGT1 in sub- Second harvest and second ABMT A second bone marrow harvest was performed 60-90 days post MGTl and 12 still contained tumour cells (before purging). At harvest, the median number of nucleated cells was 4.53 x 108 kg-' (0.95-10.6 x 108 kg-') and the median number of CFU was 24 x I04 kg-' (4.1-75 x I04 kg-'). The median number of nucleated cells and CFU grafted were respectively 0.92 x 108 kg-' (0.22-2.92 x 108 kg-') and 3.4 x 104kg-' (0.3 to 12 x 104 kg-').
Patients characteristics before MGT2, marrow recovery and response to MGT2 are summarised in Table III. Thirty of the 33 patients reached MGT2:one patient died with toxicity after the first graft, two patients with disease progression after the first graft received no MGT2 (one due to rapid death with disease, the other was a parental refusal). Median time to reach MGT2 was 3 months (range, 2-6 months) post MGT1. Five patients had achieved CR with MGT1, two additional patients with only residual local disease achieved CR before MGT2 with surgery (patient no. 31 was in 2nd CR before MGT1 and is not evaluated for response). One patient (patient no 7) died of toxicity and was not evaluable after the second graft, patient no 25 was not evaluated. Thus only 20 of the 30 patients are evaluable for the response to VCR, L-PAM and TBI. Five achieved CR and seven patients were further improved by 50% or more (PR). The response rate of these 20 patients to MGT2 is thus 60% (CR rate:25%).
Duration of aplasia was longer after MGT2 and ABMT2. The median time to reach 1000 white cells was 30 days (12-120), to reach 200 PNC cells 25 days (10-124), to reach 500 PNC cells 43 days (15-120). Twelve patients reached 50,000 platelets at a median time of 65 days (27-297). Six patients died with procedure related complications before reaching 50,000 platelets and in 12 patients the date of recovery was not reported due to their return to their transferring centers. Two patients (no. 1 and no. 27) with delayed platelets recovery died with disease. One never became independent of platelets transfusions since he experienced early relapse 3 months after MGT2 and died with progression 4 months later. The other one (no. 1) became independent after 120 days but died with disease progression one year after MGT2. Two further patients (no. 2 and no. 25) with delayed platelets recovery are alive and well after a prolonged period of platelet substitution dependency (reaching stable counts of more than 50,000 at days 189 and 297). The median time to return home was 40 days.
Three deaths due to interstitial pneumonitis occurred within the first 100 post-transplant days in two CR patients (days 35 and 78) and in one PR patient (day 41). Four further late toxic deaths were observed due to haemorrhage associated with delayed platelet recovery (one PR patient:days 118 and one CR patient:day 121), lung fibrosis in a PR patient on day 138 and renal failure with incomplete marrow engraftment in a PR patient on day 180.
Late and long term complications in the 11 survivors were documented growth impairment in one and hemosiderosis in another. The other patients appear to have normal life quality comparable to their age companions with full reintegration in their social structure.
Survival
The overall survival for the 33 patients after a median follow up time of 56 months is 36% (Figure 1 ) at 2 years and shows an actuarial 32% plateau at 5 years. Survival of patients was not influenced by the interval between diagnosis and study entry since actuarial survivals are exactly the same for patients with intervals of less or more than 12 months.
Twenty-five patients receiving MGT1/2 in first partial remission after second line treatments (with previous minor response to first line treatment) achieved an overall survival of 40% at 2 years and an actuarial survival of 34% at 5 years. Eight patients treated with MGT1/2 for relapse (one second CR, 6 second PR and one minor response) had an overall survival of 25% at 2 years (5 years not reached) (Figure 2 ). Months from first graft Figure 1 Overall survival of 33 study patients.
Fifteen patients experienced relapse or disease progression. Two patients had very early metastatic and locoregional relapses at 2 and 3 months after MGT1 and the other 13 after MGT2. The sites of relapse or progression are detailed on Table IV . Nine patients showed distant relapse (two N = 33 P= 33% tumours recurred also in the primary site) whereas in three patients primary locoregional tumour was the first site of recurrent disease. The median duration of the progression free interval was 11 months (range, 2 to 31 months) post MGT1 for the 13 patients. Eight patients died from treatment related toxicity. Thus there are ten out of 33 patients surviving relapse-free 32 to 77 months after MGTI and seven 65 78 of them more than 4 years at the time of this report. MGT followed by ABMT as consolidation treatment in neuroblastoma has been investigated by several teams in very different study populations, treating either only patients in first CR after induction or in addition patients with residual locoregional disease and/or patients in PR after one line of induction treatment (Pritchard et al., 1982; Hartmann et al., 1986; Philip et al., 1991; Graham-Pole et al., 1991a; Dini et al., 1991) but rarely patients with less sensitive disease with two or more lines of induction therapy. We report on a subgroup of stage 4 neuroblastoma patients who only achieved delayed PR after at least second line treatments or had relapsed. All received consolidation treatment that consisted of two different MGT regimens (BCNU, VM26, CDDP/or CBDCA and VCR, L-PAM, TBI), given within a 3 months interval, each one preceded by harvesting and purging of the bone marrow.
This patient cohort fulfilled in our view poor prognosis criteria at the time of inclusion. In the group of PR patients, 19 (76%) still had bone marrow involvement at first harvest after intensive pretreatments and 14 (56%) still had active (Combaret et al., 1989b Lopez et al., 1987; Gee et al., 1987) do not favour such hypothesis.
The feasibility of repeated ABMT with mafosfamid treated marrow was previously reported as safe and effective for patients after intensive chemotherapy regimens by Hartmann and Beaujean (Hartmann et al., 1987; Beaujean et al., 1989) .
In contrast, this group had collected a single large marrow harvest before MGT1. Using this divided harvest approach observed a much shorter delay in engraftment after the second ABMT than observed in our study. Thus a possible explanation for the delay of the second engraftment is damage to the micro-environment by MGT1. This is in line with a recent and earlier reports stressing the impact of treatment intensity on bone marrow recovery (Graham-Pole et al., 1991b , Kingston et al., 1984 . In addition, some of our LMCE2 patients with very late recovery showed an excess of CD8-Leu 7 cells and were thus given anti-CD8 monoclonal antibody. This was an effective treatment in some of these cases as previously reported (Favrot et al., 1990) .
Twenty-one of 33 patients included in this LMCE2 study and analysed at the time of the first harvest had residual bone marrow metastases and the question could be asked as to whether the first course of MGT (BCNU, VM26, CBDCA) was able to eliminate residual tumour cells in the bone marrow in vivo. This effect was observed in only eight of the 20 patients, with twelve patients still showing positive bone marrows at the second harvest. One patient with normal bone marrow before MGT1 even progressed with the appearance of bone marrow metastases after MGT1. In 'vivo purging' by MGT1 was not particularly efficient and therefore purging procedures appeared rational for the second harvest in most patients. Purging is however only of potential value in those cases where MGT achieves CR as any theoretical adverse effect of reinfusing tumour cells is irrelevant where significant marrow disease remains in the patient. In summary, this treatment approach achieved an encouraging survival rate of 36% at 2 years with no late relapses at the time of this report in a subgroup of poor prognosis neuroblastoma patients. The delayed engraftments and the high toxic death rate after the seond graft supports the use of a single harvest approach. This study suggests that increased dose-intensity may improve the outlook for some patients with delayed reponse or relapse and it is the task of future randomised studies to evaluate the role of such multiple high dose procedures (Shuster et al., 1991) . Modification of the MGT regimens, the use of marrow growth factors and adjunctive peripheral blood stem cell transfusion could reduce morbidity to a more acceptable level.
This work has been supported by the Institut National de la Sante et de 
